Payers like key traits of pragmatic clinical trials, but are wary of pharmaceutical companies and plan to carefully scrutinize this new, appealing type of evidence.
Don P. Buesching, PhD
Advertisement
Articles by Don P. Buesching, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Preparing Practices for the Next Era of Hepatitis B Care
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
5